Investigation of Transcript Variant 6 of TPD52L2 as a Prognostic and Predictive Biomarker in Basal-Like MDA-MB-231 and MDA-MB-453 Cell Lines for Breast Cancer

Table 2

Association between the transcript expression of V6 and clinicopathological parameters in patients with BLBC.

Clinicopathological parameters		TPD52L2 expression		value
		High (>median)	Low (<median)
Pathologic_T
T1	22	6	16	0.0099
T2	65	35	30
T3	8	7	1
T4	1	1	0
Pathologic_M
M0	94	48	46	1
M1	3	2	1
Pathologic_stage
Stage I	17	3	14	0.0101
Stage II	63	35	28
Stage III	13	9	4
Stage IV	2	1	1
Pathologic_N
N0	61	29	32	0.6541
N1	24	13	11
N2	8	5	3
N3	4	3	1

Age: at initial pathological diagnosis; pTNM: pathological tumor-node-metastasis; pT: pathological tumor; pN: pathological node. The median expression value was 4.251. The significance of correlations between V6 expression and clinicopathological parameters was calculated by the test, and Fisher’s exact test was used when the patient number had an expected .